ACENOCOUMAROL Chemical Properties

Melting point:

196-1990C

Boiling point:

486.76°C (rough estimate)

Density 

1.3979 (rough estimate)

refractive index 

1.5000 (estimate)

storage temp. 

-20°C Freezer

solubility 

DMSO, heptane and xylene: ≥17mg/mL

pka

pKa 4.7 (Uncertain)

form 

powder

color 

white to tan

Safety Information

Hazard Codes 

Xn

Risk Statements 

63-22-36/37/38

Safety Statements 

26-36/37

RIDADR 

2811

WGK Germany 

3

RTECS 

GN4900000

HS Code 

2932.20.2000

HazardClass 

6.1(b)

PackingGroup 

III

Hazardous Substances Data

152-72-7(Hazardous Substances Data)

Toxicity

LD50 orally in mice, rats: 1470, 1000 mg/kg (Leroux, Jamain)

ACENOCOUMAROL Usage And Synthesis

Chemical Properties

White Crystalline Solid

Originator

Sintrom ,Geigy ,US ,1957

Uses

R-Enantiomer of Acenocoumarol. Vitamin K antagonist; structurally similar to Warfarin. Anticoagulant

Uses

S-Enantiomer of Acenocoumarol. Vitamin K antagonist; structurally similar to Warfarin. Anticoagulant

Uses

antimicrobial

Uses

Anticoagulant agent: Vitamin K antagonist

Definition

ChEBI: A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.

Manufacturing Process

16 parts of 4-hydroxycoumarin and 19 parts of 4-nitrobenzalacetoneare thoroughly mixed and heated for 12-14 hours in an oil bath, the temperature of which is between 135°C and 140°C. After cooling, the melt is dissolved in a little acetone. The solution is slowly added to a lye made up from 6 parts of sodium hydroxide in 400 parts of water while stirring and then the mixture is stirred for 30 minutes. A little animal charcoal is then added, the mixture is stirred for a further 15 minutes, 400 parts of water are added and the charcoal and undissolved components are separated by filtration under suction. The clear solution is made acid to Congo red paper with hydrochloric acid and the product which is precipitated is filtered off under suction. 3-[α- (4'-Nitrophenyl)-β-acetylethyl]-4-hydroxycoumarin is obtained. MP 196-199°C.
It should be noted that the process is akin to that for Warfarin except that 4- nitrobenzalacetone replaces benzalacetone as a raw material.

Therapeutic Function

Anticoagulant, Vitamin

Clinical Use

Anticoagulant

Safety Profile

Poison by intraperitoneal route.Moderately toxic by ingestion. A human teratogen by anunspecified route. When heated to decomposition it emitstoxic fumes such as NOx.

Synthesis

Acenocoumarin, 3-(α-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin (24.1.11), is synthesized by a scheme completely analogous to making warfarin, but using p-nitrobenzalacetone.

Drug interactions

Potentially hazardous interactions with other drugs There are many significant interactions with coumarins. Prescribe with care with regard to the following:
Anticoagulant effect enhanced by: alcohol, amiodarone, anabolic steroids, aspirin, aztreonam, bicalutamide, cephalosporins, chloramphenicol, cimetidine, ciprofloxacin, fibrates, clopidogrel, cranberry juice, danazol, dipyridamole, disulfiram, dronedarone, esomeprazole, ezetimibe, fibrates, fluconazole, flutamide, fluvastatin, grapefruit juice, itraconazole, ketoconazole, levamisole, levofloxacin, macrolides, methylphenidate, metronidazole, miconazole, nalidixic acid, neomycin, norfloxacin, NSAIDs, ofloxacin, omeprazole, pantoprazole, paracetamol, penicillins, propafenone, ritonavir, rosuvastatin, SSRIs, simvastatin, sulfinpyrazone, sulphonamides, tamoxifen, testosterone, tetracyclines, thyroid hormones, tigecycline, toremifene, tramadol, trimethoprim, valproate, vitamin E, voriconazole.
Anticoagulant effect decreased by: acitretin, azathioprine, carbamazepine, enteral feeds, enzalutamide, fosphenytoin, griseofulvin, oral contraceptives, phenobarbital, phenytoin, primidone, rifamycins, St John’s wort (avoid), sucralfate, vitamin K.
Anticoagulant effects enhanced / reduced by: anion exchange resins, corticosteroids, dietary changes, efavirenz, fosamprenavir, tricyclics.
Analgesics: increased risk of bleeding with IV diclofenac and ketorolac - avoid concomitant use.
Anticoagulants: increased risk of haemorrhage with apixaban, dabigatran, edoxaban and rivaroxaban - avoid.
Antidiabetic agents: enhanced hypoglycaemic effect with sulphonylureas also possible changes to anticoagulant effect.
Ciclosporin: there have been a few reports of altered anticoagulant effect; decreased ciclosporin levels have been seen rarely.
Cytotoxics: increased risk of bleeding with erlotinib; enhanced anticoagulant effect with capecitabine, etoposide, fluorouracil, ifosfamide, sorafenib and tegafur; reduced effect with mercaptopurine and mitotane.

Metabolism

Acenocoumarol is extensively metabolised, although the metabolites appear to be pharmacologically inactive in man. 29% is excreted in the faeces and 60% in the urine, with less than 0.2% of the dose being renally excreted unchanged.

ACENOCOUMAROL(152-72-7)Related Product Information

• Argatroban
• PHENPROCOUMON
• ACENOCOUMAROL
• 4-Hydroxy-3-benzylcoumarin
• 3-(4-Nitrophenyl)propanoic acid
• 2-PHENYLPROPANE-2-D1
• 1-SEC-BUTYL-4-NITROBENZENE
• 1-butyl-4-nitrobenzene
• (R)-(+)-WARFARIN
• rac 7-Hydroxy Acenocoumarol
• Acenocoumarol-D5
• rac 6-Hydroxy Acenocoumarol
• ACENOCOUMAROL EPA(CRM STANDARD)
• 4-HYDROXY-3-METHYL-CHROMEN-2-ONE
• ACENOCOUMAROL USP(CRM STANDARD)
• nitrofarin
• 6-PHENOXY-HEXAN-2-ONE